ASH 2022: Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma Models that have historically been used to predict survival outcomes in advanced-stage classical Hodgkin lymphoma (A-HL) are outdated and less useful in the modern treatment era. Members of…
ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma In research presented by Nancy Bartlett, MD, a past Scientific Advisory Board (SAB) member and LRF grantee, durable clinical responses were observed in patients with relapsed/refractory follicular lymphoma…
ASH 2022: Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas Lymphomas are a potentially curable subset of cancers, but long-term treatment or disease effects may impact quality of life. Researchers, therefore, sought to determine how quality of life…
Where Are They Now? Deborah Stephens, DO When did you become interested in the study of medicine? In lymphoma specifically? I grew up on a farm, and my mom told me she knew I would go into medicine because I…
A Multi-Layered View to Lymphoma Research Some people are born to be scientists, and Eric D. Hsi, MD, Department Chair of Pathology at Wake Forest University School of Medicine, is one such person. While he may have always known he…
Where Are They Now? Paolo Strati, MD When did you become interested in the study of medicine? In lymphoma specifically? My pathway to medicine has not been linear nor as smooth as you would think, as pretty much nothing in…
Leading the Path to a Cure Through Research Born and raised in Mitchell, South Dakota, Julie M. Vose, MD, MBA, grew up in a medical family. Her father was a pathologist, and her mother was a nurse, so the goal…
Trusting the Process and Celebrating Triumphs Growing up in Cleveland, Ohio, Steven M. Horwitz, MD, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, member of LRF’s Scientific Advisory Board, and co-chair of LRF’s Lymphoma Scientific Research Mentoring Program (LSRMP),…